India's Themis Medicare hits over 1-mth high on DCGI approval

Themis Medicare

17/02/2023 06:44

** Shares of Themis Medicare Ltd  THEM.NS  rise as much as
3.2% to 1,379 rupees, hitting their highest since Jan. 5
    ** Pharma co receives approval from Drug Controller General
of India (DCGI) for import and marketing of Remifentanil
Hydrochloride 1mg/2mg for injection solution
    ** The short-acting narcotic analgesic is approved for use
in general anaesthesia for inpatient and outpatient procedures,
co said in an exchange filing
    ** Stock posts its sharpest intraday pct gain since Feb. 10
    ** Shares continue to trade above their 50-,100- and 200-day
simple moving averages
    ** More than 7,600 shares change hands by 11:58 a.m. IST,
1.3x 30-day avg of 5,968 shares
    ** Stock has fallen 1.3% so far this year up to last close;
it gained 43.5% in 2022
 (Reporting by Dimpal Gulwani in Bengaluru)
 ((dimpal.gulwani@thomsonreuters.com))